Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Reply to comment by J.P. Suarez Fernandez on “Consensus document for the diagnosis of prosthetic joint infections: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement)”
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-020-04909-5
document
Image Quality and Interpretation of [18F]-FES-PET: Is There any Effect of Food Intake?
Published in: Diagnostics
Access to document
10.3390/diagnostics10100756
document
BACKGROUND: High physiological 16α-[18F]-fluoro-17β-estradiol ([18F]-FES) uptake in the abdomen is a limitation of this positron emission tomography (PET) tracer. Therefore, we investigated the effect of food intake prior to PET acquisition on abdominal background activity in [18F]-FES-PET scans. METHODS: Breast cancer patients referred for [18F]-FES-PET were included. Three groups were designed: (1) patients who consumed a chocolate bar (fatty meal) between tracer injection and imaging (n = 20), (2) patients who fasted before imaging (n = 20), and (3) patients without diet restrictions (control group, n = 20)....
Jorianne Boers, Katerina Giatagana, Carolina P Schröder, Geke A P Hospers, Erik F J de Vries, Andor W J M Glaudemans
Correction to: Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women (European Journal of Drug Metabolism and Pharmacokinetics, (2020), 45, 5, (675-689), 10.1007/s13318-020-00635-3)
Published in: European journal of drug metabolism and pharmacokinetics
Access to document
10.1007/s13318-020-00638-0
document
Maureen G Conlan, Erik F J de Vries, Awjm Glaudemans, Yamei Wang, Steven Troy
Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women
Published in: European journal of drug metabolism and pharmacokinetics
Access to document
10.1007/s13318-020-00635-3
document
BACKGROUND AND OBJECTIVES: Advanced estrogen receptor-positive (ER+) breast cancer is currently treated with endocrine therapy. Elacestrant is a novel, nonsteroidal, selective estrogen receptor degrader with complex dose-related ER agonist/antagonist activity that is being developed as a treatment option for ER+ breast cancer. METHODS: Two first-in-human phase 1 studies of elacestrant in healthy postmenopausal women (Study 001/Study 004) were conducted to determine its pharmacokinetic and pharmacodynamic profile as well as its safety and maximum tolerated dose. RESULTS: In total, 140 postmenopausal subjects received at least one dose of study...
Maureen G Conlan, Erik F J de Vries, Awjm Glaudemans, Yamei Wang, Steven Troy
Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?
Published in: Journal of Nuclear Cardiology
Access to document
10.1007/s12350-018-01477-y
document
BACKGROUND: Nuclear imaging modalities using 123Iodine-metaiodobenzylguanidine (123I-MIBG) and bone seeking tracers identify early cardiac involvement in ATTRm amyloidosis patients. However, little is known whether results from 123I-MIBG scintigraphy actually correlate to markers for either cardiac autonomic neuropathy or cardiomyopathy. METHODS: All TTR mutation carriers and ATTRm patients who underwent both 123I-MIBG and 99mTechnetium-hydroxymethylene diphosphonate (99mTc-HDP) scintigraphy were included. Cardiomyopathy was defined as NT-proBNP > 365 ng/L, and cardiac autonomic neuropathy as abnormal cardiovascular reflexes at autonomic function tests. Late 123I-MIBG heart-to-mediastinum ratio (HMR) < 2.0 or wash-out > 20%, and any cardiac 99mTc-HDP uptake...
Daphne L Jonker, Bouke P C Hazenberg, Hans L A Nienhuis, Riemer H J A Slart, Andor W J M Glaudemans, Walter Noordzij